Actively Recruiting
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC
Led by Northern Jiangsu People's Hospital · Updated on 2026-01-09
20
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the efficacy and safety of radiotherapy combined with immunotherapy in the neoadjuvant treatment of resectable NSCLC.
CONDITIONS
Official Title
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully understand the study and voluntarily sign the informed consent form (ICF)
- Aged 18 to 70 years, any gender
- Histologically confirmed resectable stage IB-IIIA NSCLC
- At least one measurable lesion per RECIST v1.1
- Willing to provide PD-L1 immunohistochemistry slides and pathology reports
- Lesions suitable for radiotherapy as assessed by the study team
- ECOG performance status of 0-1
- Adequate organ function
- Willing and able to comply with study visits, treatments, and tests
- Sufficient pulmonary function to tolerate lung surgery as assessed by a surgeon
- Women of childbearing potential must have negative pregnancy test within 3 days before first dose
- Participants of childbearing potential must agree to use effective contraception during the study and for 180 days after last dose
You will not qualify if you...
- Locally advanced unresectable or metastatic disease
- NSCLC involving superior sulcus, large cell neuroendocrine carcinoma (LCNEC), or sarcomatoid tumors
- Known EGFR mutations or ALK translocations (non-squamous NSCLC must confirm status)
- Prior systemic anticancer therapy for early-stage NSCLC, including investigational drugs
- Contraindications or inability to undergo radiotherapy
- History or current pneumonitis/interstitial lung disease requiring steroids
- Known active tuberculosis or active infection requiring systemic therapy
- Known or suspected autoimmune disease or immunodeficiency
- Active hepatitis B infection
- Live vaccines administered within 30 days before first dose
- Grade 2 or higher peripheral neuropathy
- Prior treatment with PD-1/PD-L1 inhibitors or other T-cell targeting drugs
- History of severe hypersensitivity to monoclonal antibodies
- Severe or uncontrolled medical conditions
- Any condition that may interfere with study participation or safety as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jiangsu Northern People Hospital
Yangzhou, Jiangsu, China, 225001
Actively Recruiting
Research Team
B
Buhai Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here